Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDE2REPAIR: Olaparib + Durvalumab + Tremelimumab in HRR-mutated Solid Tumors
NCT04169841Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Feb 2020
- Primary completion
- Aug 2027
- Countries
- 1
- Sponsor
- Centre Georges-François Leclerc
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Conditions
- solid tumor
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab and olaparib in solid tumor, sponsored by Centre Georges-François Leclerc. Primary endpoint: Progression-Free Survival at 12 months. Started Feb 2020; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
GUIDE2REPAIR patients
Patients with solid tumors and HRR mutations
03
Who it enrols
Patients with solid tumors and HRR gene mutations who have progressed on prior therapies but are stable or responding to an 8-week olaparib run-in.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Disease Control Rate
Overall Survival
Response Rate
Safety Assessments
Beyond the preview
Go deeper on NCT04169841.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169841.